AbbVie’s ABBV key top-line drivers are its newer immunology medicines, Rinvoq and Skyrizi. Sales of both these drugs have effectively replaced the company’s flagship drug, Humira, which began facing ...
Please provide your email address to receive an email when new articles are posted on . Patients with refractory Crohn’s disease previously exposed to ustekinumab benefited from risankizumab. Findings ...
Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund rose 5.39% (Institutional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback